Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk Factors

Abstract

Purpose: To evaluate the incidence of clinically rel-evant cardiac toxicity after treatment with epirubicin/ paclitaxel-containing regimens in patients with meta-static breast cancer and to identify high-risk patients in whom the benefit of chemotherapy may be negated by the occurrence of congestive heart failure (CHF). Patients and Methods: A total of 105 patients who were referred for epirubicin/paclitaxel treatment were included in this study. Treatment regimens were as follows: (1) epirubicin 90 mg/m2 plus paclitaxel 135 to 225 mg/m2 over 3 hours (n 5 76); and (2) gemcitabine 1,000 mg/m2 on days 1 and 4 plus epirubicin/pacli-taxel (n 5 29). The occurrence of CHF was detected by physical examination, and left ventricular function was evaluated by bidimensional echocardiography to sup

Similar works

Full text

thumbnail-image
oai:CiteSeerX.psu:10.1.1.999.5049Last time updated on 11/2/2017

This paper was published in CiteSeerX.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.